SKUP Publishes Report on EKF Quo-Test HbA1c Anayzer

SKUP (Scandinavian Organisation for the Evaluation of Laboratory Equipment for primary health care), has published its report on the evaluation of EKF’s Quo-Test A1C system. The objective of SKUP is to improve the quality of near patient testing by supplying independent and objective information on analytical quality and ease of use of laboratory equipment.

The evaluation was carried out in Denmark during 2011 at Hillerod Hospital, Hillerod and at two primary health care centres. Patient samples from all three sites were run on both Quo-Test and on a laboratory-based A1C analyzer. Three Quo-Test instruments and three different reagent lots were used in the evaluation.

Quo-Test, which is used primarily to monitor the glycaemic status of diabetic patients, met the SKUP performance criteria for accuracy, bias and repeatability for samples in the critical clinical area which is currently set at 6.5% A1C. User-friendliness of the Quo-Test was rated as satisfactory, the highest rating on a three-point scale, at the three sites. An analysis of the results showed that the Quo-Test A1C system performed consistently across the three instruments and across the three different reagent lots that were used in the trial.

Brian Hickey, CEO of Quotient Diagnostics, the manufacturer of Quo-Test said, “Quotient Diagnostics is very pleased to have achieved such results in this rigorous and highly-regarded, independent evaluation.”

He added, “The conclusions from the SKUP trial reinforce the excellent results we have received while obtaining certification from NGSP and IFCC in the last few months. The SKUP trial has confirmed our view that the Quo-Test A1C is a suitable and reliable system for use in the monitoring of the diabetic status of patients in the primary care setting.”